Kelly D. Deck, C.P.A., currently serves as the Chief Financial Officer at INHIBRX BIOSCIENCES INC, where she plays a pivotal role in steering the financial strategy and operations of the company. With a robust background in finance and accounting, Kelly has been instrumental in driving the financial growth and stability of INHIBRX BIOSCIENCES INC since joining the firm. Her expertise as a Certified Public Accountant has been crucial in ensuring the company's compliance with financial regulations and in maintaining transparent financial reporting. Prior to her role at INHIBRX BIOSCIENCES INC, Kelly held several high-profile positions in the financial sector, gaining extensive experience in corporate finance, strategic planning, and financial analysis. She has a proven track record of successfully managing complex financial portfolios and leading teams to achieve organizational goals. Kelly's strategic insights and meticulous approach to financial management have been key factors in her success and have earned her recognition within the industry. As CFO, Kelly is responsible for overseeing all financial aspects of INHIBRX BIOSCIENCES INC, including budgeting, forecasting, and financial risk management. Her leadership has been vital in securing funding for the company's research and development initiatives, enabling INHIBRX BIOSCIENCES INC to continue its mission of advancing innovative biopharmaceutical solutions. Kelly's dedication to excellence and her strategic vision continue to propel the company forward, solidifying its position as a leader in the biopharmaceutical industry.